α-Emitters for Radiotherapy, Together with Their Decay Progeny
| Parent | Daughters | t½ | α-decay | α-energy (MeV) | Other emission | Radiochemistry | Free isotope accumulation | Study | |
| 211At* | 7.2 h | 42% | 5.87 | Tin precursor, prosthetic group | Thyroid, stomach, spleen, lung | (15) | |||
| 211Po | 0.52 s | 100% | 7.45 | Kα x-rays (77–92 keV) | |||||
| 207Bi | 38 y | 100% electron capture | |||||||
| 207Po | Stable | ||||||||
| 225Ac* | 9.9 d | 100% | 5.94 | DOTA, DO3A chelator | Liver, bone | (21,56) | |||
| 221Fr† | 4.9 m | 100% | 6.45 | 218 keV γ | Kidneys, urine | ||||
| 217At | 32.3 ms | >99.9% | 7.20 | ||||||
| 213Bi*† | 45.6 m | 2.2% | 5.87 | 492 keV β− (97.8%); 440 keV γ | CHX-A″-DTPA, DOTA, NETA | Kidneys, urine | (50) | ||
| 213Po | 3.72 μs | 100% | 8.38 | ||||||
| 209Tl | 2.16 m | 660 keV β− (100%) | |||||||
| 209Pb | 3.23 h | 198 keV β− (100%) | |||||||
| 209Bi | Stable | ||||||||
| 227Th* | 18.7 d | 100% | 6.14 | 50 and 236 keV γ | DOTA, Me-3,2-HOPO | Bone surface | (25) | ||
| 223Ra* | 11.4 d | 100% | 5.71 | 269 keV γ | Bone surface | (57) | |||
| 219Rn | 3.96 s | 100% | 6.82 | 271 keV γ | |||||
| 215Po | 1.78 ms | >99.9% | 7.39 | ||||||
| 211Pb† | 36.1 m | 471 keV β− (100%); 404 keV γ | Blood, liver, skeleton, kidneys | (58) | |||||
| 211Bi† | 2.14 m | 99.7% | 6.62 | 172 keV β− (0.3%); 351 keV γ | Kidneys, urine | (58) | |||
| 207Tl | 4.77 m | 492 keV β− (100%) | |||||||
| 207Pb | Stable | ||||||||
| 224Ra* | 3.63 d | 100% | 5.69 | 241 keV γ | Bone surface | (30) | |||
| 220Rn† | 55.6 s | 100% | 6.29 | ||||||
| 216Po | 0.15 s | 100% | 6.78 | ||||||
| 212Pb*† | 10.6 h | 93.5 keV β− (100%); 238 and 300 keV γ | TCMC | Blood, liver, skeleton, kidneys | (31,32) | ||||
| 212Bi*† | 60.6 m | 36% | 6.05 | 834 keV β− (64%); 727 and 1,620 keV γ | CHX-A″-DTPA, DOTA, NETA | Kidneys, urine | (32) | ||
| 212Po | 0.30 μs | 100% | 8.78 | ||||||
| 208Tl | 3.1 m | 342, 441, 535, and 649 keV β− (100%); 2,614 keV γ | |||||||
| 208Pb | Stable |